<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01798251</url>
  </required_header>
  <id_info>
    <org_study_id>CGOG20120101009</org_study_id>
    <nct_id>NCT01798251</nct_id>
  </id_info>
  <brief_title>XELOX With Capecitabine Maintenance or XELOX in Elderly Metastatic Adenocarcinoma of Stomach</brief_title>
  <official_title>A Randomized Single Center Phase II Study Comparing XELOX With Capecitabine Maintenance or XELOX Treatment in Elderly Metastatic Adenocarcinoma of Stomach</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Harbin Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Harbin Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To confirm the efficacy and safety of XELOX with capecitabine maintenance in treatment of
      elderly advanced gastric cancer (AGC) by comparing it with that of XELOX regimen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To investigate whether XELOX with capecitabine maintenance treatment as 1st line treatment in
      the elderly advanced gastric cancer is as effective and safe as XELOX regimen.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>from the date of randomization until death from any cause or up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rate (RR)</measure>
    <time_frame>evaluate every 6 weeks after the date of randomization until diease progress or up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events (AE)</measure>
    <time_frame>from date of randomization to 28 days after the last chemo dosage</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>health-related quality of life (HRQOL)</measure>
    <time_frame>evaluate every 6 weeks from the date of randomization until 28 days after the last chemo dosage</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>excision repair cross-complementing 1(ERCC1) expression</measure>
    <time_frame>assays messager ribonucleic acid (mRNA) of ERCC1 expression in tumor tissue after randomization and before the first treatment</time_frame>
    <description>quantitative real-time reverse transcriptase polymerase chain reaction (PCR) assays were performed to determine ERCC1 mRNA expression in tumor tissue.</description>
  </other_outcome>
  <other_outcome>
    <measure>K-ras gene type</measure>
    <time_frame>assess after randomization and before the first treatment</time_frame>
    <description>Genomic Deoxyribonucleic acid (DNA) is extracted from tumor tissue, direct sequencing technique is used to test K-ras gene type(mutation or wild).</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>XELOX-X</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>XELOX: Oxaliplatin: 100mg/m2 d1 Intravenous infusion, every 3 weeks. Capecitabine: 850mg/m^2 bid, days 1-14, every 3 weeks and maximum 4 cycles, or progression/intolerance.
X Maintenance: Capecitabine 850mg/m^2 bid, days 1-14, every 3 weeks after 4 cycles XELOX regimen, until progression/intolerance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>XELOX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>XELOX: Oxaliplatin 100mg/m2 d1 Intravenous infusion, every 3 weeks. Capecitabine 850mg/m^2 bid, days 1-14, every 3 weeks, until progression/intolerance.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Oxaliplatin 100mg/m2 d1 Intravenous infusion every 3 weeks</description>
    <arm_group_label>XELOX-X</arm_group_label>
    <arm_group_label>XELOX</arm_group_label>
    <other_name>L-OHP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>capecitabine 850mg/m2 bid, d1-14, every 3 weeks</description>
    <arm_group_label>XELOX-X</arm_group_label>
    <arm_group_label>XELOX</arm_group_label>
    <other_name>XELODA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ages Eligible for Study: 65 Years or older

          -  Genders Eligible for Study: Both

          -  The Eastern Cooperative Oncology Group (ECOG) status â‰¤ 2

          -  Histologically confirmed gastric adenocarcinoma(including LAUREN type).

          -  Measurable disease(according to the Response Evaluation Criteria in Solid Tumors
             (RECIST) criteria 1.1).

          -  chemotherapy naive after recurrence or metastasis. Previous neo-adjuvant or adjuvant
             treatment for gastric cancer, if applicable, more than 6 months.

          -  Hb &gt; 90g/L, neutrophil count &gt; or = 1.5*10^9/L, platelet &gt; or = 100*10^9/L, alanine
             transaminase (ALT) and aspartate aminotransferase (AST) &lt; or = 2.5 times upper limit
             of nominal (ULN), alkaline phosphatase (ALP) &lt; or = 2.5 times ULN, total bilirubin
             (TBIL) &lt; 1.5 times ULN, serum albumin level &gt; or = 30g/L, serum creatinine &lt; 1 times
             ULN.

          -  No serious concomitant diseases which could lead to death within 5 years. At least 5
             years from the last Biological/Immunotherapy/Hormone treatment for Malignancy
             excluding gastric cancer.

          -  Able to accept oral medication

          -  Compliance with protocol

        Exclusion Criteria:

          -  Had received cytotoxic chemotherapy, radiotherapy or immunotherapy for this gastric
             cancer, excluding Corticosteroids.

          -  Other previous malignancy within 5 year, except curative skin cancer or carcinoma in
             situ of uterine cervix.

          -  Uncontrolled epilepsy, central nervous system disorders, or a history of mental
             disorders.

          -  clinically significant(i.e. active)cardiac disease e.g. symptomatic coronary artery
             disease, New York Heart Association (NYHA) II or more serious congestive heart failure
             or severe requiring medication intervention arrhythmia, or history of myocardial
             infarction within the last 12 months.

          -  Upper gastrointestinal obstruction or physiological dysfunction or suffering from
             malabsorption syndrome, which could affect the absorption of capecitabine.

          -  Organ transplantation requires immunosuppressive treatment.

          -  Severe uncontrolled recurrent infections, or Other serious uncontrolled concomitant
             diseases.

          -  Moderate or severe renal impairment(creatinine clearance (CCr) = or &lt; 50 ml/min), or
             serum creatinine &gt; ULN.

          -  Known enzyme deficiency of dihydropyrimidine dehydrogenase(DPD).

          -  Allergy to Oxaliplatin or any study medication ingredients.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuxian BAI, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The tumor hospital of Harbin medical university</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yuxian BAI, PhD</last_name>
    <phone>86 451 86298265</phone>
    <email>bai_yuxian@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hong SUI, PhD</last_name>
    <phone>86 13936592698</phone>
    <email>doctorsui2003@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The tumor hospital of Harbin medical university</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuxian BAI, PhD</last_name>
      <phone>86 451 86298265</phone>
      <email>bai_yuxian@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Hong SUI, PhD</last_name>
      <phone>86 13936592698</phone>
      <email>doctorsui2003@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yuxian BAI, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hong SUI, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2012</study_first_submitted>
  <study_first_submitted_qc>February 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2013</study_first_posted>
  <last_update_submitted>May 3, 2013</last_update_submitted>
  <last_update_submitted_qc>May 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Harbin Medical University</investigator_affiliation>
    <investigator_full_name>BAI Yuxian</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Elderly Gastric Cancer</keyword>
  <keyword>Capecitabine Maintenance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

